LMTK2 and cystic fibrosis: LMTK2 depletion increased the efficacy of the CFTR corrector VX-809 (Lumafactor), currently a component of Orkambi, a FDA approved drug for CF patients homozygous for the most common disease-causing mutation F508del (Luz et al., 2014).